Mountain rescue Teams called after lone walker 'fainted' on England's highest peak
A LONE walker was rescued from England's highest peak after fainting and was 'having difficulty breathing'.
Wasdale Mountain Rescue Team were called out to Brown Tongue, Scafell Pike at 9:04pm yesterday, May 3 after a kind passer-by stopped to help and called the incident into the team.
The casualty was transferred to a stretcher and taken to awaiting ambulance crew.
In a statement on social media, Wasdale Mountain Rescue Team said: "The team was called when a lone walker had fainted and was then having difficulty breathing and shivering. A very kind passer-by had stopped to help and called it in.
"Once the team was on scene an assessment was made. She was transferred to the team stretcher and then a routine carry was made to Brackenclose. After further assessment by an awaiting ambulance crew the walker was able to be discharged.
"We hope the walker has recovered well and would like to recognise the walker who gave up her 3 peaks challenge to provide help to someone in need."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Alcohol should have labels warning drinkers of cancer risks, charities say
Cans and bottles of beer, wine and spirits should explicitly warn drinkers that alcohol causes cancer, an unprecedented alliance of doctors, charities and public experts have said. Warning labels would tackle 'shockingly low' public awareness in the UK that alcohol is proven to cause seven forms of cancer and 17,000 cases a year of the disease, they claim. Dozens of medical and health organisations have written to Keir Starmer urging him to take the radical step of compelling alcohol producers to include such warnings in order to improve public health. The labels must be 'bold and unambiguous', said the World Cancer Research Fund (WCRF), which coordinated the letter. 'The evidence is clear: health labelling on alcoholic drinks is urgently needed in the UK to help save lives,' it said. 'They should carry strong, clear messages about the health risks, which include the risk of cancer, far beyond vague advice like 'consume in moderation'.' Kate Oldridge-Turner, the WCRF's head of policy and public affairs, said: 'Providing alcohol warning labels would empower millions to make informed choices by clearly understanding the risks.' Evidence cited by charities such as the WCRF and Cancer Research UK shows that alcohol increases the risk of breast, bowel, stomach, head, neck, liver and mouth cancer. Ireland is to become the first country in the world to include cancer warning labels on alcoholic products. From next May, alcohol sold in the republic will have to carry a warning that 'there is a direct link between alcohol and fatal cancers'. The labels will also warn that drinking can cause liver disease and affect foetuses. Prof Sir Ian Gilmore, the chair of the Alcohol Health Alliance, urged the UK to follow suit. He said: 'We must look to the fearless work of our neighbours in Ireland whose new labelling policy provides a level playing field for all producers, leaving no room for loopholes or hiding information behind QR codes or tiny print. 'Improved alcohol labelling, including clear health warnings about the link to cancer, is not just a public health measure, it's a fundamental consumer right. People deserve to know the risks so they can make informed choices about their health. But current labels and weak regulations are keeping drinkers in the dark.' The drinks industry dismissed the call and said warnings would make drinkers anxious. A spokesperson for the Portman Group, a drinks industry-funded body that oversees alcohol labelling in the UK, said: 'Whilst we do not dispute the link between alcohol and certain cancers, and that drinking at harmful levels is dangerous and increases risks, blanket cancer warning labels are not a proportionate policy measure and do not put the risks into an appropriate context. 'This can create unnecessary anxiety, eroding trust in health advice and alienating the very people who require support.' The spokesperson said most alcohol products already included advice from the chief medical officers of the UK's four home nations to drink no more than 14 units of alcohol a week. 'Most people already drink within this guidance, which means their risks for associated diseases are low', they said. In February, the World Health Organization's European office declared: 'Clear and prominent health warning labels on alcohol, which include a specific cancer warning, are a cornerstone of the right to health.' In a report, it urged governments to introduce them to help reduce alcohol-related harm and raise awareness of the link between drinking and cancer. Dr Gauden Galea, a WHO adviser, said in the report that policymakers should 'resist all the pressure that will inevitably come from commercial actors' who claim such warnings do not work. In January, Vivek Murthy, the US surgeon general under the then president, Joe Biden, said cancer warning labels were needed because drinking led to about 100,000 cancer diagnoses a year in the US. It was the third most common preventable cause of cancer after tobacco and obesity, he added. A Department of Health and Social Care spokesperson said: 'Drinking alcohol increases the risk of a range of health issues, including several cancers. That is why we recommend people drink within the UK chief medical officer's alcohol guidelines of fewer than 14 units a week, and strongly recommend these are displayed clearly on all alcohol products. 'We recognise the need for more action on the impact of alcohol on health; for too long there has been an unwillingness to lead on this issue. Our plan for change will shift healthcare towards prevention, including through early intervention, to support people to live longer, healthier lives across the UK.'
Yahoo
an hour ago
- Yahoo
Submit your feedback to help shape the future of pharmacy services
York and North Yorkshire residents are being asked to help shape the future of pharmacy services in their area. Feedback from a previous consultation, on whether the locations, accessibility, and services provided by pharmacies are adequate, have already been used to draw up plans for the future. Those plans, which have been incorporated into the Pharmaceutical Needs Assessment, are the subject of a new 60-day consultation underway from Friday (June 20), with the window for feedback to close on Tuesday, August 19. Following this new consultation, the Humber and North Yorkshire Integrated Care Board will decide how pharmacy services are to be commissioned in York and North Yorkshire. Feedback received so far has influenced decisions on, for example, pharmacy opening hours. The survey, which is predicted to take between ten and 15 minutes to complete, can be accessed at
Yahoo
6 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
